Early Access to EMRs May Improve the Patient Experience in Oncology
Joleen Hubbard, MD, explains why allowing access to results can improve patient’s outlook on treatments and understanding of their disease.
EMA Validates Application for Subcutaneous Nivolumab in Solid Tumors
The European Medicines Agency will begin a centralized review process for subcutaneous nivolumab across multiple solid tumor indications.
Golidocitinib Receives Chinese Approval in Relapsed/Refractory PTCL
Golidocitinib monotherapy had a superior clinical benefit in patients with relapsed/refractory peripheral T-cell lymphoma vs existing treatments.
AI-Assisted Contours Exhibit High Accuracy in Evaluating Prostate Cancer
Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.
Capivasertib Combo Earns European Approval in ER+/HER2– Breast Cancer
Data from CAPItello-291 support the approval of capivasertib/fulvestrant for ER-positive, HER2-negative breast cancer in the European Union.
Cryoablation Approach Linked to Shorter Hospitalizations, High Recurrence-Free Rate for Kidney Cancer
A minimally invasive cryoablation technology system designed to treat patients with kidney tumors and elicit an 89.65% recurrence-free rate.
Robotic Hepatectomy May Demonstrate Safety in Liver Cancer
Findings from a retrospective study showed that outpatient robotic hepatectomies resulted in no mortalities across 307 procedures.
Expert Highlights Risk Factors for Disease Progression in Polycythemia Vera
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Sonrotoclax Combo Shows Enduring Responses in Relapsed/Refractory CLL/SLL
Phase 1 data show no dose-limiting toxicities with sonrotoclax plus zanubrutinib for patients with relapsed/refractory CLL or SLL.
No Ruxolitinib Benefit Reduction Noted After Myelofibrosis-Related Anemia
Data from the phase 3b JUMP trial support the use of ruxolitinib in myelofibrosis regardless of baseline or treatment-related anemia.
Capivasertib Combo Does Not Meet OS End Points in Advanced TNBC
Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.
Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice
Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.
TP53-Mutated Disease Confers Worse Chronic Lymphocytic Leukemia Outcomes
Progression-free survival and overall survival appear to be shorter in patients with TP53-mutant CLL vs those with TP53 wild-type disease.
FDA Approval Alert: Amivantamab Plus Chemotherapy in Non-Small Cell Lung Cancer
Misako Nagasaka, MD, PhD, discussed the approval of amivantamab plus chemotherapy for patients with EGFR exon 20 insertion mutations non–small cell lung cancer.
Trajectories of Change in Physical Wellbeing Reported for AML Subgroups
Four trajectories of change were identified in FACT-PWB score, with large patient groups experiencing little to no change or slight declines in PWB.
FDA Places Partial Hold on BNT326/YL202 Trial for NSCLC, Breast Cancer
A trial for BNT326/YL202 in EGFR-mutated NSCLC or HR-positive HER2-negative breast cancer has paused enrollment due to a large illness or injury risk.
Novel Antibody Lock Solution Improves Time to Failure Event in Common Cancer-Related Infection
The novel antibiotic lock solution Mino-Lok could help treat catheter-related infections that patients with cancer may experience.
BLA Submitted in Subcutaneous Amivantamab in EGFR-mutated NSCLC
Data from the phase 3 PALOMA study showed subcutaneous amivantamab had comparable ORR to intravenous administration for patients with EGFR-mutated NSCLC.
Linvoseltamab Shows Lasting Responses in Relapsed/Refractory Myeloma
Phase 1/2 data highlight the benefit of linvoseltamab even among prespecified high-risk patient subgroups with relapsed/refractory multiple myeloma.
Continued Quizartinib May Show Benefit in Select FLT3-ITD+ AML Population
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Pembrolizumab/Chemo Receives OK From FDA in Advanced Endometrial Cancer
Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.
Ide-cel Continues to Yield Deep Responses in High-Risk Multiple Myeloma
A cohort study of the KarMMa-2 trial found durable responses in patients with high-risk multiple myeloma treated with ide-cel.
UGN-102 Shows Durable 1-Year Responses in Low-Grade, Intermediate-Risk NMIBC
UGN-102 also demonstrated a 79.6% complete response rate at 3 months in the phase 3 ENVISION trial.
Lower Tumor Burden Increases Liso-cel Response Likelihood in R/R CLL/SLL
The likelihood of response was also higher in patients who received no more than 3 lines of therapy prior to liso-cel in the TRANSCEND CLL 004 trial.
Product Profile of Amivantamab Plus Chemotherapy in EGFR Exon 20+ NSCLC
Tammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
“Promising” Data Support Blinatumomab in CD19+ B-ALL Population
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Applying Updated Breast Cancer Findings From ASCO to Clinical Practice
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Learning the IORT Mechanism, Potential Advantages in Cancer Surgery
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.
Zanubrutinib Has Cost Savings, QALY Benefits vs Acalabrutinib in B-Cell Cancers
Treatment with zanubrutinib (Brukinsa) was found to have cost savings and quality-adjusted life year benefits compared with acalabrutinib (Calquence) in patients with B-cell malignancies.
